Pharmaceutics

This page contains key pharmaceutical news on drug recalls, FDA clearance, safety communications and research. In cardiology, key pharmaceutic agents include antiplatelet therapies, anticoagulants, hypertension drugs, and drugs for heart failure and arrhythmias.

FDA approves acoramidis, BridgeBio’s new ATTR-CM drug
Acoramidis, a selective transthyretin stabilizer being sold under the brand name Attruby, is now the second ATTR-CM medication to gain FDA approval.
Medtronic receives key FDA clearance, launches new diabetes system
Medtronic designed its new Smart MDI system to provide real-time insights to users on multiple daily injection therapy.
ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data
Cardiovascular Business spoke with cardiologist Daniel Judge, MD, about the long-term benefits of acoramidis, a new drug therapy that just received FDA approval to treat transthyretin amyloid cardiomyopathy.
Martha Gulati highlights 'exciting' progress in preventive cardiology
Martha Gulati, MD, spoke to Cardiovascular Business at AHA Scientific Sessions 2024 about key developments in obesity treatment and CVD prevention.
Cardiologist examines the latest breakthroughs in coronary inflammation research
Deepak Bhatt, MD, MPH, MBA, spoke to Cardiovascular Business about the growing importance of evaluating coronary inflammation in heart patients. There has been an explosion of interest in this area since the FDA's 2023 clearance of colchicine.

Black, Hispanic AFib patients less likely to start anticoagulant therapy, new VA study finds

Researchers wrote that they hope their findings can help guide the creation of policies that reduce disparities in care for AFib patients.

November 18, 2021

High-dose icosapent ethyl treatment makes minimal impact on non-hospitalized COVID-19 patients

The analysis, presented at AHA Scientific Sessions 2021, included approximately 2,000 symptomatic COVID-19 patients who were not necessarily sick enough to be hospitalized.

November 16, 2021

Statin use may increase the risk of severe illness among COVID-19 patients

The new analysis emphasized, however, that COVID-19 mortality did not appear to be affected by prior statin use.

October 28, 2021

Many nonvalvular AFib patients skip DOAC therapy altogether

The study's authors hope their work can help with the development of new interventions that target this issue.

October 25, 2021

The exact effect of statin use on COVID-19 outcomes remains unclear

Researchers examined data from nearly 470,000 patients.

October 25, 2021

Half-dose DOAC improves outcomes after LAAO

The new-look anticoagulation strategy was associated with a significant reduction in adverse outcomes.

October 19, 2021

FDA announces recall of 2 hypertension medications

The affected batches were distributed from October 2018 to December 2020.

October 14, 2021

The pandemic's impact on statin prescriptions

The analysis, published in Circulation: Cardiovascular Quality and Outcomes, included more than 20,000 patient encounters.

September 24, 2021

Around the web

Health Imaging

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging

New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Pharmaceutics

FDA approves acoramidis, BridgeBio’s new ATTR-CM drug

Medtronic receives key FDA clearance, launches new diabetes system

ATTR-CM drug acoramidis, now approved by the FDA, linked to positive long-term data

Martha Gulati highlights 'exciting' progress in preventive cardiology

Cardiologist examines the latest breakthroughs in coronary inflammation research

Around the web